SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 199.34+0.1%3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Russian Bear who wrote (20267)5/8/1998 10:57:00 PM
From: Henry Niman  Read Replies (1) of 32384
 
Here's part of Legg Mason's morning notes:
LIGAND PHARMACEUTICALS, INC. (LGND) Analyst: Stefan D. Loren, Ph.D.
PRICE 52-WEEK EPS - (FY Dec) P/E RATIO DIV SHRS MKT CAP LT DEBT INV./RISK TARGET
5/7/98 PRICE RANGE 1997A 1998E 1999E 1998E 1999E YIELD OUT(M) $M TO CAP RATINGS PRICE
$13 15/16 $18-$10 ($1.06) ($1.03) $0.08 NM NM Nil 38.6 $536 60% B/4 $20
Legg Mason Wood Walker, Inc. makes a market in this security.
ú Ligand currently has four products in mid- to late-stage clinical trials providing a framework for near-term revenue
growth.
ú The company has a strong research pipeline, an essential factor for long-term revenue growth.
ú A steady flow of clinical and regulatory announcements, and potential new strategic alliances should lead to
increased visibility of Ligand and its discovery and development efforts.
ú The company utilizes a strong proprietary platform technology base that has an established track record for lead
discovery, and has attracted corporate partners.
ú Strategic alliances with six of the top-20 companies provide R&D funds, added technical expertise, and validation
of Ligand's drug discovery efforts.
ú Our 10-year discounted cash flow model yields a 12-18 month price target of $20 per share
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext